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Purpose: S100A8 is a member of the S100 protein family containing 2EF-hand cal-
cium-binding motifs. S100 proteins are involved in the regulation of a number of cellular 
processes such as cell cycle progression and differentiation. Altered expression of this 
protein is associated with various diseases and cancers. The present study aimed to 
evaluate whether S100A8 has prognostic value for non-muscle-invasive bladder cancer 
(NMIBC).
Materials and Methods: A total of 103 primary NMIBC samples obtained by transure-
thral resection were evaluated. mRNA levels were examined by real-time reverse tran-
scriptase polymerase chain reaction (RT-PCR) analysis. The results were compared 
with clinico-pathological parameters. The Kaplan-Meier method was applied to plot 
the curves for progression-free survival. The multivariate Cox regression model was 
used to identify the independent prognostic factors for progression.
Results: mRNA expression levels of S100A8 were significantly related to the pro-
gression of NMIBC. Kaplan-Meier estimates demonstrated significant differences in 
tumor progression according to the level of S100A8 expression (log-rank test, p＜0.001). 
The multivariate Cox regression model revealed that the S100A8 mRNA expression 
level (hazard ratio: 12.538; 95% confidence interval: 2.245-70.023, p=0.004) was an in-
dependent predictor for disease progression of NMIBC. 
Conclusions: Expression levels of S100A8 might be a useful prognostic marker for dis-
ease progression of NMIBC.
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INTRODUCTION
Bladder cancer (BC), the incidence and mortality of which 
increases directly with age, is the second most common uro-
logical malignancy in Korea and is about 5 times as com-
mon in men as in women [1]. Over 70% of human BCs are 
non-muscle-invasive bladder cancer (NMIBC) that can be 
treated by transurethral resection (TUR). However, after 
TUR about three-quarters of patients confront tumor re-
currence within 2 years, and 20-30% of patients experience 
progression to muscle-invasive bladder cancer (MIBC) 
even with complete TUR and intravesical therapy with ba-
cillus Calmette-Guérin (BCG) [2]. Useful prognostic varia-
bles such as grade, stage, tumor diameter, and presence of 
carcinoma in situ (CIS) and various biological makers have 
been proposed to assess the prognosis of BC [3-6]. But the 
efficacy of these variables is inadequate to accurately pre-
dict the heterogeneous behavior of BC, and new reliable 
molecular indicators are required.
The S100 proteins belong to the calcium-binding 
EF-hand motif superfamily and play essential roles in epi-
thelial tissues, where they are involved in a wide range of 
cellular processes including transcription, proliferation, 
and differentiation [7,8]. At least 16 genes of the S100 fam-
ily, including the gene coding for S100A8, are clustered on 
human chromosome 1q21, a frequent target region for 
chromosomal rearrangements that occur during tumor de-
velopment [9,10]. S100A8, one of the S100 calcium binding 
proteins, was described to be up-regulated in many cancers 
including BC and has been implicated in regulating cell 
proliferation and metastatic processes [11-14].
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patients with NMIBC for adequate management, for ex-
ample, early radical cystectomy has a superior 5-year sur-
vival rate in comparison with bladder-sparing surgery 
[15]. To our knowledge, few studies have evaluated the 
prognostic value of S100A8 as a marker of disease pro-
gression in NMIBC. So, we performed real-time reverse 
transcriptase polymerase chain reaction (RT-PCR) to 
quantify mRNA expression levels of S100A8 in NMIBC tis-
sues and assessed its prognostic value for tumor recurrence 
and progression in NMIBC.
MATERIALS AND METHODS
1. Patients and tissue samples
We used bladder cancer specimens harvested between 
1995 and 2007 from 103 patients at our institution with pri-
mary BC in whom transitional cell carcinoma had been di-
agnosed histologically. Tumors were staged and graded ac-
cording to standard criteria; tumor grade was determined 
by the 1973 WHO classification [4,16]. To reduce confound-
ing factors that might affect the analyses, and to make the 
study population more homogeneous, we excluded any pa-
tients diagnosed with a concomitant carcinoma in situ. 
Collection and analysis of all samples were approved by the 
Institutional Review Board (IRB approved protocol num-
ber 2006-01-001), and informed consent was obtained from 
each subject.
All tumors were macro-dissected, typically within 15 
minutes of surgical resection. Each bladder cancer speci-
men was confirmed as being representative by analysis of 
adjacent tissue in fresh frozen sections from TUR speci-
mens and was then frozen in liquid nitrogen and stored at 
−80
oC until RNA was extracted.
A second TUR was performed 2-4 weeks after the initial 
resection when it was incomplete or when a high-grade or 
T1 tumor was detected [4]. Patients who had multiple tu-
mors or large tumors (≥3 cm of diameter) or high-grade 
NMIBC received one cycle of intravesical BCG treatment 
[4,17]. Response to treatment was assessed by cystoscopy 
and urinary cytology. Patients who were free of disease in 
3 months after treatment were assessed every 3 months for 
the first 2 years and every 6 months thereafter [4,17]. We 
defined recurrence as the recurrence of primary NMIBC 
with a lower or the same pathologic stage, and progression 
as disease with a higher TNM stage.
2. RNA extraction and construction of cDNA
One milliliter TRIzol (Invitrogen, Carlsbad, USA) was add-
ed to BC tissue and homogenized in a 5 ml glass tube. The 
homogenate was transferred to a 1.5 ml tube and was mixed 
with 200μl chloroform. After incubation for 5 min at 4
oC, 
the homogenate was centrifuged for 13 min at 13,000 g at 
4
oC. The upper aqueous phase was transferred to a clean 
tube and 500μl isopropanol was added, followed by in-
cubation for 60 min at 4
oC. The tube was then centrifuged 
for 8 min at 13,000 g and 4
oC. Then, the upper aqueous 
phase was discarded, mixed with 500μl of 75% ethanol, 
and centrifuged for 5 min at 13,000 g and 4
oC. After the up-
per aqueous layer was discarded, the pellet was dried at 
room temperature, dissolved with diethylpyrocarbonate 
(DEPC)-treated water, and stored at −80
oC.
The quality and integrity of RNA were confirmed by 
agarose gel electrophoresis and ethidium bromide stain-
ing, followed by visual examination under ultraviolet light. 
cDNA was then prepared from 1μg of random priming by 
using a First-Strand cDNA Synthesis Kit (Amersham 
Biosciences Europe GmbH, Freiburg, Germany) according 
to the manufacturer’s protocol.
3. Real-time PCR
To quantify the expression levels of S100A8, real-time PCR 
amplification was performed with a Rotor Gene 6000 in-
strument (Corbett Research, Mortlake, Australia). Real- 
time PCR assays using SYBR Premix EX Taq (TAKARA 
BIO INC., Otsu, Japan) were carried out in micro-reaction 
tubes (Corbett Research, Mortlake, Australia).
The primers used for amplifying S100A8 (185 bp) were 
5’-CAT CGA CGT CTA CCA CAA GT-3’ and 5’-GAA TGA 
GGA ACT CCT GGA AG-3’. The PCR reaction was per-
formed in a final volume of 10μl, consisting of 5μl of 2x 
SYBR premix EX Taq buffer, 0.5μl of each 5’- and 3’- primer 
(10 pmol/μl), and 1μl of the sample cDNA. The product was 
purified with a QIAquick Extraction kit (QIAGEN, Hilden, 
Germany), quantified with a spectrometer (Perkin Elmer 
MBA2000, Fremont, USA), and sequenced with an auto-
mated laser fluorescence sequencer (ABI PRISM 3100 
Genetic Analyzer, Foster City, USA). The known concen-
tration of the product was 10-fold serially diluted from 100 
pg/μl to 0.1 pg/μl. The dilution series of PCR products were 
used for establishing the standard curve of real-time PCR.
The real-time PCR conditions were 1 cycle at 96
oC for 
20 seconds, followed by 40 cycles of 2 seconds at 96
oC for 
denaturation, 15 seconds at 60
oC for annealing, and 15 sec-
onds at 72
oC for extension. The melting program was per-
formed at 72-95
oC with a heating rate of 1
oC per 45 seconds. 
Spectral data were captured and analyzed by using Rotor- 
Gene Real-Time Analysis Software 6.0 Build 14 (Corbett 
Research, Mortlake, Australia). All samples were run in 
triplicate. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was applied as an endogenous RNA reference 
gene. Gene expression was normalized to the expression of 
GAPDH.
4. Statistical analysis
Because of its highly skewed distribution, the S100A8 
mRNA data were examined as the natural log function and 
were subsequently back transformed for the interpre-
tation of the model results [18]. Student’s t-test was applied 
to assess the association of the mRNA expression level for 
the clinical variables. The optimal cutoff for the mRNA lev-
el was determined by using a receiver operating character-
istics (ROC) curve. The Kaplan-Meier method was used to 
estimate the time to recurrence and progression, and dif-
ferences were assessed by using log rank statistics. The Korean J Urol 2010;51:15-20
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FIG. 1. Receiver operating characteristic (ROC) curve generated 
for progression with the S100A8 mRNA expression level in 
non-muscle-invasive bladder cancer. AUC: area under the curve.
TABLE 1. Clinical and pathological features of the non-muscle-in-
vasive bladder cancer
Variables No. of patients (%)
Age (years)
Sex
Male
Female
Grade
Low (grade 1 and 2)
High (grade 3)
Stage
TaN0M0
T1N0M0
Size
＜3 cm
≥3 cm
Number
Single
Multiple
S100A8 expression
Low
High
Intravesical therapy
No
Yes
Recurrence
No
Yes
Progression
No
Yes
66.0 (24.0-88.0)
87 (84.5)
16 (15.5)
87 (84.5)
16 (15.5)
23 (22.3)
80 (77.7)
56 (54.4)
47 (45.6)
63 (61.2)
40 (38.8)
77 (74.8)
26 (25.2)
47 (45.6)
56 (54.4)
67 (65.0)
36 (35.0)
92 (89.3)
11 (10.7)
TABLE 2. mRNA expression levels of S100A8 in non-muscle-in-
vasive bladder cancer
Variables 
mRNA expression level
(x10
3 copies/μl) 
p-value
Grade
Low (grade 1 and 2)
High (grade 3)
Stage
TaN0M0
T1N0M0
Size
＜3 cm
≥3 cm
Number
Single
Multiple
30.9 (19.8-48.1)
315.1 (141.2-703.5)
28.6 (13.7-59.8)
50.2 (30.3-83.4)
39.5 (23.3-67.1)
50.8 (25.2-102.4)
25.3 (15.7-41.0)
106.8 (51.7-221.0)
＜0.001
　0.275
　0.561
　0.001
prognostic value of the expression level of S100A8 in 
NMIBC was studied by use of multivariate Cox propor-
tional hazards regression models. Statistical analysis was 
performed by using SPSS 12.0 software (SPSS Inc., 
Chicago, USA), and p-values of ＜0.05 were considered 
statistically significant.
RESULTS
1. Baseline characteristics
The mean follow-up period of the 103 primary NMIBC pa-
tients was 58.2 months (median, 52.2; range, 3.2-137.0). A 
total of 80 of 103 patients (77.7%) who were reported as hav-
ing T1 or higher grade received repeat TUR for adequate 
tumor staging. During the follow-up period, 36 of 103 sub-
jects (35.0%) experienced recurrence and 11 of 103 (10.7%) 
experienced progression. Two patients with Ta progressed 
into T1, and the other 9 patients into muscle-invasive or 
metastatic disease. The mean intervals of recurrence and 
progression were 44.0 months (median, 31.5; range, 3.0- 
137.0) and 55.8 months (median, 51.8; range, 3.2-137.0), 
respectively. Other clinical and pathological features of the 
enrolled patients are presented in Table 1.
2. Quantification of the S100A8 mRNA expression level
Table 2 summarizes the expression levels of S100A8 ac-
cording to the clinical factors associated with the prognosis 
of NMIBC. The mRNA expression levels of S100A8 in 
high-grade and multiple tumors were higher than in lower 
grade or single tumors, respectively (p＜0.05). There was 
no significant difference in the expression level of S100A8 
between patients without recurrence and those with re-
currence (p=0.978). S100A8 mRNA levels were sig-
nificantly higher in the patients with progression than in 
those without progression (p=0.047).
3. Relations between mRNA expression levels of S100A8 
mRNA and recurrence and progression
The associations between the S100A8 mRNA expression 
level and the time to recurrence and progression were 
analyzed. Recurrent-free survival was not related to the 
S100A8 mRNA expression level. The cutoff (171.2x10
3 cop-
ies/μl) for progression with the highest combined sensi-
tivity (63.6%) and specificity (79.3%) was determined on Korean J Urol 2010;51:15-20
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TABLE 3. Univariate and multivariate Cox regression analysis for prediction of disease progression
Variables
Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value
Age (＜66 years vs. ≥66 years)
Stage (Ta vs. T1)
Grade (low vs. high)
Number (single vs. multiple)
Size (＜3 cm vs. ≥3 cm)
S100A8 (low vs. high)
  2.553 (0.723-9.010)
  0.970 (0.255-3.693)
  5.305 (1.485-18.959)
  4.575 (1.302-16.078)
  1.307 (0.398-4.294)
10.512 (2.684-41.166)
0.145
0.965
0.010
0.018
0.660
0.001
−
−
1.461 (0.353-6.039)
6.877 (1.533-30.853)
−
12.538 (2.245-70.023)
−
−
0.601
0.012
−
0.004
HR: hazards ratio, CI: confidence interval
FIG. 2. Time to progression in non-muscle-invasive bladder 
cancer with S100A8 mRNA expression levels.
the ROC curve (Fig. 1). The patients with decreased 
S100A8 mRNA expression had significant progression- 
free survival benefits compared with those with high ex-
pression (log-rank test, p＜0.001) (Fig. 2). In addition to 
grade and tumor number, which are already well-known 
risk factors, S100A8 mRNA expression was a significant 
risk factor for progression-free survival in the univariate 
analysis (Table 3). Multivariate Cox regression analyses 
revealed that the S100A8 expression level (hazard ratio: 
12.538, 95% confidence interval: 2.245-70.023, p=0.004) 
was significantly associated with progression in the pa-
tients with primary NMIBC (Table 3).
DISCUSSION
The S100 protein family includes more than 20 entities, all 
of which are identified only in vertebrates, that share a 
common structure carrying the calcium-binding EF-hand 
motif [8]. S100 proteins are low molecular weight, acidic 
peptides of 9-13 kDa and are involved in the regulation of 
cell cycle progression, cell growth, differentiation, secre-
tion, and cytoskeletal organization. Most of the S100 pro-
teins, including S100A8, are located in a gene cluster on 
chromosome locus 1q21, a region in which several re-
arrangements that occur during tumor development have 
been observed [9,10]. The functions of S100 proteins in tu-
morigenesis and tumor progression have not been clearly 
elucidated, but recent reports have suggested that S100 
proteins are commonly up-regulated in tumors and this is 
often associated with tumor progression [14]. Overex-
pressed S100 proteins in the colon and the breast include 
S100A1, S100A4, S100A6, S100A7, and S100B [19]. A 
number of reports have also described how S100 proteins 
are involved in the progression of various cancers [20,21].
Few studies have been conducted on S100A8 expression 
in BCs. The expression of S100A8 was ranked as 1 of 100 
genes that would suggest an aggressive phenotype among 
tumors with protein expression [22]. Tolson et al showed 
S100A8 to be highly expressed in tumor cells in contrast 
with normal urothelium in MIBC and suggested S100A8 
as a potential diagnostic and prognostic maker of BC [13]. 
Yao et al proved that S100A8 is significantly overexpressed 
in BC of rats, mice, and humans [12].
In this report, we investigated the mRNA expression 
levels of S100A8 in human primary NMIBC tissue. Our da-
ta showed that overexpression of S100A8 protein in pri-
mary NMIBC was strongly associated with progression in 
patients with NMIBC. However, overexpression of S100A8 
was not associated with tumor recurrence. These results 
imply that S100A8 may contribute to the generation of cer-
tain aspects of the aggressive phenotype rather than sim-
ply promoting cell proliferation in NMIBC. The over-
expression of S100A8 and S100A9 has also been shown to 
be associated with poor pathological parameters in in-
vasive ductal carcinoma of the breast [23]. Yong and Moon 
revealed a functional contribution of S100A8 proteins to 
processes required for malignant progression including in-
vasion in human gastric cancer cells [11]. Hermani et al 
suggested that S100A8 may contribute to development and 
progression or extension of the prostate carcinomas [24]. 
These results collectively suggest that induction of S100A8 
expression may represent aggressive features, such as pro-
gression and invasion, in human solid cancers.
There are several possible reasons for the close associa-
tion of the S100A8 protein with BC and its progression. 
First, chromosome 1q has been known to exhibit chromoso-
mal rearrangements in various human tumors, including 
1q21-24 in BC [25]. As mentioned previously, most S100 
proteins, including S100A8, are clustered at the chromo-
some locus 1q21. Second, the chromosomal region 1q21- Korean J Urol 2010;51:15-20
S100A8 as a Prognostic Marker of NMIBC 19
q22 contains a high density of CpG islands. Hypermethyla-
tion of CpG islands has been shown to be a common mecha-
nism for the inactivation of tumor suppressor genes and is 
also found in BC [26,27].
There were some limitations in our study. We did not 
evaluate the protein level of S100A8, such as by Western 
blot or immunohistochemical staining. We think that fur-
ther protein study of S100A8 will be needed to confirm its 
function as a more reliable prognostic marker. In our study, 
T stage did not predict progression. These discrepancies 
may reflect differences in the distribution of our patient 
population. In our population group, the number of T1 pa-
tients was larger than the number of Ta patients. Some-
how, conventional histopathologic evaluation, encompass-
ing cancer grade and stage, is inadequate to accurately pre-
dict the behavior of most bladder cancers, since there were 
heterogeneous population groups enrolled in studies 
[28,29]. Therefore, there has been considerable interest in 
identifying biological indicators of individual tumor 
aggressiveness. Our finding that the expression of S100A8 
was a reliable prognostic indicator of progression for 
NMIBC, independent of traditional pathologic prognostic 
parameters, may be an important and valuable con-
tribution to the management of BC.
CONCLUSIONS
S100A8 mRNA levels were significantly higher in patients 
with progression than in those without progression. The 
patients with decreased S100A8 mRNA expression had 
significant progression-free survival benefits compared 
with those with high expression. The expression of S100A8 
was an independent prognostic parameter for tumor 
progression. Thus, expression levels of S100A8 might be a 
useful prognostic marker for disease progression of 
NMIBC.
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